Clinical Trial Update: HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

View source ↗

Summary

A completed retrospective study sponsored by AstraZeneca aims to estimate the prevalence of HER2-low status among unresectable or metastatic breast cancer patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Breast Neoplasms, Breast Cancer | Status: COMPLETED